Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company...